Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagloxad simolenin (OPT-822) in Metastatic Breast Cancer
NCT01516307Phase 2Completed
- Sponsor
- OBI Pharma
- Start
- Dec 2011
- Primary completion
- Aug 2016
- Modality
- Therapeutic Vaccines, Split/Subunit Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of adagloxad simolenin in breast cancer, sponsored by OBI Pharma. Started Dec 2011; status: completed.
02
Drugs
adagloxad simolenin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01516307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516307.